EGFR ERBB3(HER3)/CT26
CBP73357
| I. Introduction | |
|
Cell Line Name： |
EGFR ERBB3/CT26 |
|
Host Cell: |
CT26 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
|
Freeze Medium: |
90% FBS+10% DMSO |
|
Complete Culture Medium: |
RPMI-1640+10%FBS+10ug/ml puromycin+20ug/ml blasticidin |
|
Mycoplasma Status: |
Negative |
|
II. Background |
|
|
EGFR (HER1), epidermal growth factor receptor, is a tyrosine kinase receptor, which activates RAS/RAF/MEK and PI3K/AKT/mTOR pathways, leading to increased cell proliferation and growth. EGFR activating mutations, amplification, and overexpression are found in a variety of tumors, including non-small cell lung cancer and colorectal cancer, and the EGFRvIII variant is commonly found in glioblastoma . ERBB3, erb-b2 receptor tyrosine kinase 3, encodes HER3, which is one of three ERBB members of the EGFR receptor tyrosine kinase family, which activates PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways to promote cell survival and proliferation. Activating Erbb3 mutations have been observed in a several tumor types, including lung and gastric and colon adenocarcinomas and Erbb3 mutations are also associated with acquired drug resistance. |
|
|
|
|
| Ⅲ. Representative Data | |
|
1.Anti-proliferation assay
Figure 1. Recombinant EGFR ERBB3/CT26 constitutively expressing EGFR. |
|
